- Home
- VSTM vs VALN Comparison
VSTM vs VALN Comparison
Compare VSTM & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | VALN |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.8M | 820.0M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VSTM | VALN |
|---|---|---|
| Price | $7.89 | $9.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $13.38 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 1.9M | 24.9K |
| Earning Date | 11-04-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $13,379,000.00 | ★ $211,089,992.00 |
| Revenue This Year | $208.54 | $3.64 |
| Revenue Next Year | $251.40 | $12.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.79 | 13.48 |
| 52 Week Low | $4.01 | $4.20 |
| 52 Week High | $11.25 | $12.25 |
Technical Indicators
Market Signals| Indicator | VSTM | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 63.27 |
| Support Level | $6.68 | $8.77 |
| Resistance Level | $8.88 | $10.03 |
| Average True Range (ATR) | 0.55 | 0.36 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 54.09 | 86.07 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.